With deep experience in FDA regulatory law and health policy consulting, we advise patient advocates, global life science and innovative emerging companies on product approvals and regulatory reforms, drafting and enacting Federal legislation, and securing funding or creating new P3s...
Offering 30+ years of Federal health
policy and legislative insights, as former congressional committee staff, policy advisor, and leader of national FDA law and Federal affairs practices
Read our Milbank Quarterly essays on FDA in the Trump Administration and the Orphan Drug Act's 40th anniversary or our Health Affairs Forefront essays on HHS Secretary Kennedy and vaccines and on mifepristone.
We can help develop effective strategies to engage Federal agencies like HHS, FDA, NIH, CDC, ARPA-H and BARDA.
Our clients have included Fortune 500 and innovative startup biopharmas, leading patient groups, coalitions, life science trade associations, and innovators in Europe, South Korea and Israel.
Our solutions are grounded in sound policy, a clear understanding of the law, and the best clinical evidence - helping advance public health for all.
If your issue is at CMS or requires Federal lobbying, we know trusted consulting partners who are national experts in their domains.
Feel free to call or message with your health policy question. Let's discuss the issue and find some new approaches...
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.